{
    "Trade/Device Name(s)": [
        "COBAS INTEGRA Glucose HK New Formulation",
        "Glucose HK New Formulation",
        "Gluc2"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "K062239",
    "Predicate Device Reference 510(k) Number(s)": [
        "K972250"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CFR"
    ],
    "Summary Letter Date": "September 11, 2006",
    "Summary Letter Received Date": "August 2, 2006",
    "Submission Date": "August 1, 2006",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma",
        "Urine",
        "Cerebrospinal fluid"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "COBAS INTEGRA SYSTEMS"
    ],
    "Method(s)/Technology(ies)": [
        "Enzymatic reference method with hexokinase"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Reagent",
        "System",
        "Cassette"
    ],
    "Document Summary": "FDA 510(k) summary for COBAS INTEGRA Glucose HK New Formulation enzymatic assay for quantitative glucose determination on COBAS INTEGRA systems",
    "Indications for Use Summary": "In vitro test for the quantitative determination of glucose in serum, plasma, urine and cerebrospinal fluid (CSF) on COBAS INTEGRA systems; used in diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus and idiopathic hypoglycemia",
    "fda_folder": "Clinical Chemistry"
}